Phase 1/2Terminated
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Lung Cancer (NSCLC)
- Sponsor
- Clovis Oncology, Inc. (Industry)
- Enrollment
- 7 enrolled
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Rociletinib; Trametinib
- Ages
- adults, older adults
- Registry
- NCT02580708
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib when administered in combination with trametinib.
Primary outcomes
- Incidence of treatment-emergent adverse events
- Objective Response Rate (ORR)
- Cmax of rociletinib and trametinib at steady state
- Tmax of rociletinib and trametinib at steady state
History
Last registry update
Study completion
Primary completion
Registered
Started